医麦客新闻 eMedClub News 近日,Mesoblast Limited(以下简称“Mesoblast”)宣布,其同种异体间充质前体细胞(MPC)药物rexlemestrocel-L的验证性3期试验已经在美国开始招募患者,适应症为因炎症性退行性椎间盘疾病引起的慢性腰痛(CLBP)。 新闻...
A high-level overview of Mesoblast Limited (MESO) stock. View (MESO) real-time stock price, chart, news, analysis, analyst reviews and more.
Mesoblast Limited (ASX:MSB) Clear To Proceed With Angioblast AcquisitionAsia Business News
医麦客新闻 eMedClub News 近日,MesoblastLimited(以下简称“Mesoblast”)宣布,其同种异体间充质前体细胞(MPC)药物rexlemestrocel-L的验证性3期试验已经在美国开始招募患者,适应症为因炎症性退行性椎间盘疾病引起的慢性腰痛(CLBP)。 新闻稿指出,rexlemestrocel-L已获FDA再生医学高级疗法(RMAT)及提交生物制品许可申...
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive Silviu Itescu will deliver the Featured Presentation at the Intern...
医麦客新闻 eMedClub News 近日,Mesoblast Limited(以下简称“Mesoblast”)宣布,其同种异体间充质前体细胞(MPC)药物rexlemestrocel-L的验证性3期试验已经在美国开始招募患者,适应症为因炎症性退行性椎间盘疾病引起的慢性腰痛(CLBP)。 新闻稿指出,rexlemestrocel-L已获FDA再生医学高级疗法(RMAT)及提交生物制品许可...
TipRanks Australian Auto-Generated Newsdesk A+ A- Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has announced the departure of director Joseph Swedish, effective November 15, 2024. Swedish holds 1,327,077 options and 45,942 American Depositary Shares, representing his fina...
Mesoblast Limited Sponsored ADR股价创历史新低,2023年12月6日盘中跌8.40%,近五个交易日跌21.01%。该公司在同种异体细胞药物开发方面处于世界领先地位。 同花顺 2025年02月07日 星期五 02-07 23:45 利好 Piper Sandler重申Mesoblast评级为增持 最新目标价24.00美元 PiperSandler重申Mesoblast评级为增持,最新...
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. or By creating an account using any of the options above, you agree to theTerms of Use&Privacy Policy MESOMesoblast Limited
MesoblastLimited (MEOBF) 宣布DREAM-HF随机对照III期试验的附加结果,该试验对537名接受rexlemestrocel-L (REVASCOR®) 或对照组的慢性心力衰竭左室射血分数降低(HFrEF)患者进行治疗。 单剂量rexlemestrocel-L可显著降低心脏病发作、中风和心脏病死亡。目前,现有的治疗方法对这些终点只有很小的益处或没有益处,此次...